Previous 10 | Next 10 |
Evofem Biosciences (NASDAQ: EVFM ) -26% after pricing equity offering. More news on: Evofem Biosciences, Inc., Cellectar Biosciences, Inc., Reinsurance Group of America, Incorporated, Stocks on the move, , Read more ...
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it received notice from The Nasdaq Stock Market, LL...
Gainers: Ameri Holdings (NASDAQ: AMRH ) +152% . More news on: Ameri Holdings, Inc., Westwater Resources, Inc., Genius Brands International, Inc., Stocks on the move, , Read more ...
Are These Biotech Penny Stocks On Your List Right Now? One of the hottest sectors this year is biotechnology. No matter if you like momentum, speculation, fundamentals, etc. there are plenty of biotech penny stocks to watch in 2020. With that, it’s important to understand some of the ...
Westwater Resources (NASDAQ: WWR ) +144% on positive independent test results on ULTRA-PMG. More news on: Westwater Resources, Inc., Tenax Therapeutics, Inc., BioHiTech Global, Inc., Stocks on the move, , Read more ...
Tenax Therapeutics (NASDAQ: TENX ) is up 79% premarket after announcing positive Phase 2 results for levosimendan for the treatment of patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). More news on: Tenax Therapeutics, Inc., H...
- Demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures - Demonstrated a significant improvement with 6-minute walk distance - No significant safety issues. - Management to host conference call and webcast today at 8:30 a.m...
Top-line Data Readout Remains on Track for Late Q2 2020 Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today a...
Thinly traded nano cap Tenax Therapeutics ( TENX -43.3% ) slumps on increased volume, a modest 72K shares, on the heels of its direct at-the-market offering of 750K common shares at $1.1651 and pre-funded warrants to purchase up to ~1.6M common shares at $0.0001 at $1.1650 per warrant. ...
HELP study exceeds target enrollment with 37 patients 84% initial open-label lead-in response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced, on average, by 7.5 mmHg during exercise following the initial levosimendan infusion No serious ...
News, Short Squeeze, Breakout and More Instantly...
Tenax Therapeutics Inc. Company Name:
TENX Stock Symbol:
NASDAQ Market:
Tenax Therapeutics Inc. Website:
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent ...
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF Provides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond ...